<h4>Background</h4>The safety of pembrolizumab monotherapy in treatment-naïve non-small cell lung cancer (NSCLC) patients with high programed death-ligand 1 (PD-L1) expression and pre-existing interstitial lung disease (ILD) has not yet been determined. This evidence concerns the gene CD274 and non-small cell lung carcinoma.